Johnson & Johnson Pharmaceutical Research & Development, LLC (CA) Release: Rivaroxaban Phase II Dose-Ranging Study Demonstrates Encouraging Response Rates in Treatment of Acute Coronary Syndrome Patients

NEW ORLEANS--(BUSINESS WIRE)--Findings from the Phase II ATLAS ACS TIMI 46 study of rivaroxaban, a novel, investigational, oral anticoagulant, were presented today as a late-breaking clinical trial at the American Heart Association’s Scientific Sessions 2008 in New Orleans by C. Michael Gibson, M.D., director of the TIMI Data Coordinating Center, Harvard Medical School. Results from this Phase II study support advancing rivaroxaban into a pivotal Phase III trial for the secondary prevention of acute coronary syndrome (ACS).